Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ESPR NASDAQ:ETON NASDAQ:REPL NASDAQ:RLMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeESPREsperion Therapeutics$3.15-0.2%$2.54$0.69▼$4.18$809.52M0.918.56 million shs12.89 million shsETONEton Pharmaceuticals$30.79+2.1%$22.42$13.09▼$32.31$842.41M0.82345,964 shs218,530 shsREPLReplimune Group$3.28-4.7%$5.80$1.50▼$13.24$271.57M0.123.89 million shs1.34 million shsRLMDRelmada Therapeutics$7.45-5.3%$6.45$0.34▼$8.00$778.70M0.431.44 million shs246,402 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceESPREsperion Therapeutics+1.12%+64.92%+23.53%-0.94%+222.91%ETONEton Pharmaceuticals-0.76%+27.86%+20.60%+110.10%+81.67%REPLReplimune Group+19.23%+43.78%-59.93%-50.62%-54.37%RLMDRelmada Therapeutics+6.94%+6.65%+13.91%+118.33%+2,100.45%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeESPREsperion Therapeutics$3.15-0.2%$2.54$0.69▼$4.18$809.52M0.918.56 million shs12.89 million shsETONEton Pharmaceuticals$30.79+2.1%$22.42$13.09▼$32.31$842.41M0.82345,964 shs218,530 shsREPLReplimune Group$3.28-4.7%$5.80$1.50▼$13.24$271.57M0.123.89 million shs1.34 million shsRLMDRelmada Therapeutics$7.45-5.3%$6.45$0.34▼$8.00$778.70M0.431.44 million shs246,402 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceESPREsperion Therapeutics+1.12%+64.92%+23.53%-0.94%+222.91%ETONEton Pharmaceuticals-0.76%+27.86%+20.60%+110.10%+81.67%REPLReplimune Group+19.23%+43.78%-59.93%-50.62%-54.37%RLMDRelmada Therapeutics+6.94%+6.65%+13.91%+118.33%+2,100.45%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceESPREsperion Therapeutics 2.00Hold$5.5475.87% UpsideETONEton Pharmaceuticals 2.40Hold$39.3330.46% UpsideREPLReplimune Group 1.60Reduce$4.7538.81% UpsideRLMDRelmada Therapeutics 2.71Moderate Buy$12.0052.67% UpsideCurrent Analyst Ratings BreakdownLatest REPL, ESPR, RLMD, and ETON Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/4/2026ESPREsperion Therapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold5/1/2026ESPREsperion Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/1/2026ESPREsperion Therapeutics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/1/2026ESPREsperion Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/1/2026ESPREsperion Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/1/2026ESPREsperion Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$3.164/24/2026REPLReplimune Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/21/2026ESPREsperion Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026ETONEton Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/17/2026ETONEton Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/13/2026REPLReplimune Group Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Hold(Data available from 5/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookESPREsperion Therapeutics$403.14M2.01N/AN/A($1.26) per share-2.50ETONEton Pharmaceuticals$79.95M10.32$0.01 per share5,861.24$0.98 per share30.77REPLReplimune GroupN/AN/AN/AN/A$5.40 per shareN/ARLMDRelmada TherapeuticsN/AN/AN/AN/A$1.18 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateESPREsperion Therapeutics-$22.68M-$0.17N/A14.322.53-3.66%N/A-3.93%5/7/2026 (Estimated)ETONEton Pharmaceuticals-$4.60M-$0.18N/A16.57N/A-5.75%-2.60%-0.66%5/14/2026 (Estimated)REPLReplimune Group-$247.30M-$3.44N/AN/AN/AN/A-102.69%-72.22%5/28/2026 (Estimated)RLMDRelmada Therapeutics-$57.38M-$1.45N/AN/AN/AN/A-170.83%-145.58%5/11/2026 (Estimated)Latest REPL, ESPR, RLMD, and ETON EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/28/2026Q4 2026REPLReplimune Group-$0.73N/AN/AN/A$0.95 millionN/A5/14/2026Q1 2026ETONEton Pharmaceuticals$0.10N/AN/AN/A$22.31 millionN/A5/11/2026Q1 2026RLMDRelmada Therapeutics-$0.18N/AN/AN/AN/AN/A5/7/2026Q1 2026ESPREsperion Therapeutics-$0.04N/AN/AN/A$84.52 millionN/A3/19/2026Q4 2025ETONEton Pharmaceuticals$0.12$0.05-$0.07$0.05$20.58 million$21.28 million3/19/2026Q4 2025RLMDRelmada Therapeutics-$0.14-$0.27-$0.13-$0.27N/AN/A3/10/2026Q4 2025ESPREsperion Therapeutics$0.23$0.22-$0.01$0.22$165.12 million$168.45 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthESPREsperion TherapeuticsN/AN/AN/AN/AN/AETONEton PharmaceuticalsN/AN/AN/AN/AN/AREPLReplimune GroupN/AN/AN/AN/AN/ARLMDRelmada TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioESPREsperion TherapeuticsN/A1.541.19ETONEton Pharmaceuticals0.831.571.17REPLReplimune Group0.335.605.60RLMDRelmada TherapeuticsN/A14.6114.61Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipESPREsperion Therapeutics47.39%ETONEton Pharmaceuticals27.86%REPLReplimune Group92.53%RLMDRelmada Therapeutics45.24%Insider OwnershipCompanyInsider OwnershipESPREsperion Therapeutics1.70%ETONEton Pharmaceuticals16.49%REPLReplimune Group5.20%RLMDRelmada Therapeutics14.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableESPREsperion Therapeutics200257.40 million253.03 millionOptionableETONEton Pharmaceuticals2027.36 million22.85 millionOptionableREPLReplimune Group21082.57 million78.28 millionOptionableRLMDRelmada Therapeutics10104.89 million89.68 millionOptionableREPL, ESPR, RLMD, and ETON HeadlinesRecent News About These CompaniesRelmada Therapeutics (NASDAQ:RLMD) Reaches New 1-Year High - Time to Buy?May 6 at 6:35 PM | marketbeat.comRelmada Therapeutics to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026May 6 at 7:00 AM | globenewswire.comRelmada Therapeutics to Present NDV-01 Abstracts at AUA2026May 5 at 7:00 AM | globenewswire.comRelmada Therapeutics (RLMD) Projected to Post Quarterly Earnings on MondayMay 4 at 12:36 PM | marketbeat.comMizuho Securities Remains a Buy on Relmada Therapeutics (RLMD)April 16, 2026 | theglobeandmail.comRelmada Therapeutics (NASDAQ:RLMD) Trading Down 4.3% - Here's What HappenedApril 16, 2026 | marketbeat.comRelmada Therapeutics, Inc. (NASDAQ:RLMD) Given Average Recommendation of "Moderate Buy" by BrokeragesApril 14, 2026 | marketbeat.comRelmada Therapeutics, Inc. (NASDAQ:RLMD) Sees Large Increase in Short InterestApril 13, 2026 | marketbeat.comDoes Relmada Therapeutics (RLMD) Have the Potential to Rally 75.58% as Wall Street Analysts Expect?April 13, 2026 | zacks.comRelmada Therapeutics (NASDAQ:RLMD) Hits New 12-Month High - Should You Buy?April 9, 2026 | marketbeat.com5 Small Drug Stocks to Buy as Sector Recovery Gains StrengthApril 2, 2026 | zacks.comRelmada Therapeutics: 2 New Assets, 2 New 'Blockbusters'? I'd Wait And SeeMarch 30, 2026 | seekingalpha.comWall Street Analysts Predict a 92.19% Upside in Relmada Therapeutics (RLMD): Here's What You Should KnowMarch 26, 2026 | zacks.comHere’s What Makes Mizuho Bullish on Relmada Therapeutics Inc (RLMD) StockMarch 25, 2026 | msn.comRelmada wins bullish view at Piper Sandler on cancer therapyMarch 24, 2026 | seekingalpha.comPiper Sandler initiates coverage of Relmada Therapeutics (RLMD) with overweight recommendationMarch 24, 2026 | msn.comRelmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2025 earnings call transcriptMarch 20, 2026 | msn.comRelmada Therapeutics Inc (RLMD) Q4 2025 Earnings Call Highlights: Strategic Advancements and ...March 20, 2026 | sg.finance.yahoo.comRelmada Therapeutics, Inc. (RLMD) Q4 2025 Earnings Call TranscriptMarch 19, 2026 | seekingalpha.comRelmada (RLMD) Q4 2025 Earnings Call TranscriptMarch 19, 2026 | fool.comRelmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business UpdateMarch 19, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 20263 Dividend Aristocrats Whose Yields Can Help Combat InflationBy Chris Markoch | April 9, 2026Bitcoin and Big Tech Rally as Risk Appetite Returns, Even With Ceasefire UncertaintyBy Jessica Mitacek | April 21, 2026The Drone Disruptor: Kratos Stock Seeks a Higher Altitude By Jeffrey Neal Johnson | April 8, 2026The PDT Rule Is On Its Way Out: 5 Stocks That Stand to Benefit the MostBy Ryan Hasson | April 20, 2026REPL, ESPR, RLMD, and ETON Company DescriptionsEsperion Therapeutics NASDAQ:ESPR$3.14 -0.01 (-0.16%) As of 12:27 PM Eastern This is a fair market value price provided by Massive. Learn more.Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.Eton Pharmaceuticals NASDAQ:ETON$30.79 +0.64 (+2.12%) As of 12:27 PM Eastern This is a fair market value price provided by Massive. Learn more.Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.Replimune Group NASDAQ:REPL$3.28 -0.16 (-4.65%) As of 12:26 PM Eastern This is a fair market value price provided by Massive. Learn more.Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.Relmada Therapeutics NASDAQ:RLMD$7.44 -0.42 (-5.28%) As of 12:27 PM Eastern This is a fair market value price provided by Massive. Learn more.Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Anheuser-Busch Stock Jumps as Volume Growth Signals Turnaround Light Speed Returns: Corning Cashes In on NVIDIA Growth Boarding Passes Now Being Issued for the Ultimate eVTOL Arbitrage DigitalOcean’s AI Surge: How Far Can This Rally Go? Fairy Dust Works: Disney's Stock Price Rises as Business Accelerates Apple Talks Just Changed Everything for Intel Consolidate or Die: Is Rivian The Ultimate Takeover Target? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
